ARLZ - Aralez Pharmaceuticals Inc.
| Previous Close | 1.44 |
| Open | 1.40 |
| Bid | 1.35 x 5000 |
| Ask | 1.39 x 500 |
| Day's Range | 1.36 - 1.42 |
| 52 Week Range | 0.95 - 2.98 |
| Volume | 175,369 |
| Avg. Volume | 571,769 |
| Market Cap | 89.465M |
| Beta | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.89 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2013-12-31 |
| 1y Target Est | 4.33 |
- Thomson Reuters StreetEvents•19 days ago
Edited Transcript of ARLZ earnings conference call or presentation 13-Mar-18 12:30pm GMT
Q4 2017 Aralez Pharmaceuticals Inc Earnings Call
- Simply Wall St.•25 days ago
Will Aralez Pharmaceuticals Inc’s (TSE:ARZ) Earnings Grow In The Next Couple Of Years?
The latest earnings update Aralez Pharmaceuticals Inc’s (TSX:ARZ) released in December 2017 suggested company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...
- GlobeNewswire•25 days ago
Eyenovia Appoints Three Industry Veterans to Board of Directors
NEW YORK, March 26, 2018-- Eyenovia, Inc., a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics ...
- Zacks Small Cap Research•last month
ARLZ: Aralez Set for Strong Revenue Growth in 2018
Aralez (ARLZ) launched Zontivity® in June 2017 and is now promoting the drug with the company’s 75 person sales force to approximately 12,000 cardiologists, primary care physicians, and vascular surgeons. During the fourth quarter of 2017, Aralez saw a 22% increase in new prescriptions compared to the third quarter of 2017 along with a 32% increase in total prescriptions and a 39% increase in retail prescription equivalents (RPEs). The company uses the RPE metric, which is defined as the total pill count divided by 30, to better reflect the fact that many Zontivity® prescriptions are for more than a 30-day supply.
CNW Group•last monthAralez Announces Fourth Quarter and Full-Year 2017 Financial Results
Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
- PR Newswire•last month
Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
-4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016- -Full-Year Net Revenues Increased to $105.9 Million Versus $54.3 Million in Full-Year 2016- -Provides 2018 Full-Year ...
- ACCESSWIRE•last month
Aralez Pharmaceuticals Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Aralez Pharmaceuticals Inc. (NASDAQ: ARZ ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 13, 2018, at 8:30 AM Eastern ...
- GlobeNewswire•2 months ago
Select Sands Appoints Mr. Daniel Gillett and Mr. Steven Goldman to the Board of Directors
VANCOUVER, British Columbia, March 06, 2018-- Select Sands Corp. is pleased to announce it has appointed Mr. Steven Goldman to the board of directors.. Gillett joins the board with over 30 years experience ...
- CNW Group•2 months ago
Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
- PR Newswire•2 months ago
Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
-Executive Management to Host Conference Call on March 13, 2018 at 8:30 a.m. ET - MISSISSAUGA, Ontario , March 6, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced ...
- Simply Wall St.•2 months ago
How Financially Strong Is Aralez Pharmaceuticals Inc (TSE:ARZ)?
Investors are always looking for growth in small-cap stocks like Aralez Pharmaceuticals Inc (TSX:ARZ), with a market cap of CA$139.12M. However, an important fact which most ignore is: how financiallyRead More...
- Simply Wall St.•2 months ago
Why Aralez Pharmaceuticals Inc (TSE:ARZ) Could Be A Buy
Aralez Pharmaceuticals Inc (TSX:ARZ), a pharmaceuticals company based in Canada, led the TSX gainers with a relatively large price hike in the past couple of weeks. As a stock withRead More...
- PR Newswire•3 months ago
Aralez to Present at the 2018 BIO CEO and Investor Conference
MISSISSAUGA, Ontario , Jan. 30, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate ...
- CNW Group•3 months ago
Aralez to Present at the 2018 BIO CEO and Investor Conference
Aralez to Present at the 2018 BIO CEO and Investor Conference
- Simply Wall St.•3 months ago
Is Aralez Pharmaceuticals Inc (TSE:ARZ) On The Right Side Of Disruption?
Aralez Pharmaceuticals Inc (TSX:ARZ), a CADCA$149.82M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population,Read More...
- Simply Wall St.•4 months ago
Does Aralez Pharmaceuticals Inc’s (TSE:ARZ) CEO Salary Compared Well With Others?
Adrian Adams took the reins as CEO of Aralez Pharmaceuticals Inc’s (TSX:ARZ) and grew market cap to CA$127.08M recently. Understanding how CEOs are incentivised to run and grow their companyRead More...
- Simply Wall St.•4 months ago
Who Are The Major Shareholders In Aralez Pharmaceuticals Inc (TSE:ARZ)?
In this article, I’m going to take a look at Aralez Pharmaceuticals Inc’s (TSX:ARZ) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Simply Wall St.•5 months ago
Where Aralez Pharmaceuticals Inc (TSX:ARZ) Stands In Terms Of Earnings Growth Against Its Industry
When Aralez Pharmaceuticals Inc’s (TSX:ARZ) announced its latest earnings (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I usedRead More...
Capital Cube•5 months agoAralez Pharmaceuticals, Inc. :ARLZ-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
Categories: Yahoo FinanceGet free summary analysis Aralez Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Aralez Pharmaceuticals, Inc. – Horizon Pharma plc, Johnson & Johnson, Pfizer Inc., Astrazeneca PLC Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie, Inc. and Eli Lilly ... Read more (Read more...)
- CNW Group•5 months ago
Aralez Announces Departure of Chief Financial Officer
Aralez Announces Departure of Chief Financial Officer
- PR Newswire•5 months ago
Aralez Announces Departure of Chief Financial Officer
MISSISSAUGA, Ontario, Nov. 30, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company") today announced that Scott J. Charles, Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately. Michael Kaseta will assume the position of Interim Chief Financial Officer ("CFO") along with his current duties as Corporate Controller. Mr. Kaseta has served as Corporate Controller since 2016 and brings a breadth of experience in all aspects of the Company's financial operations.
- Simply Wall St.•5 months ago
Are Aralez Pharmaceuticals Inc’s (TSX:ARZ) Interest Costs Too High?
Aralez Pharmaceuticals Inc (TSX:ARZ) is a small-cap stock with a market capitalization of CAD CA$133.77M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...
- Zacks Small Cap Research•5 months ago
ARLZ: Increasing Revenue Projections for 2018
Aralez (ARLZ) launched Zontivity® in June 2017 and is now promoting the drug with the company’s 75 person sales force to approximately 12,000 cardiologists, primary care physicians, and vascular surgeons. During the third quarter of 2017 Aralez reported all-time highs in both new prescriptions (NRx) and total prescriptions (TRx), as they increased 151% and 82%, respectively. Thus far, 65% of Zontivity® prescriptions are written by cardiologists, 24% from primary care physicians, and 4% from vascular surgeons.
- ACCESSWIRE•5 months ago
Today’s Research Reports on Stocks to Watch: Aralez Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Sage Therapeutics stole the show on Thursday, with gains of over 50% at the close. The company presented positive data with analysts responding ...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of ARLZ earnings conference call or presentation 9-Nov-17 1:30pm GMT
Q3 2017 Aralez Pharmaceuticals Inc Earnings Call
